Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Earnings release
confidence 98%
filed 2026-09-23
EX-99.1
This is a corporate press release announcing Manchester United's fourth quarter and full-year fiscal 2026 financial results, dated 23 September 2026. The exhibit discloses record full-year revenue of £677.6 million, adjusted EBITDA of £216.4 million, and a net loss of £43.0 million, along with detailed revenue analysis by segment (Commercial, Broadcasting, Matchday) and forward guidance for fiscal 2027. This is a classic earnings release event material to investors assessing the registrant's financial performance and outlook.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-23
Item 8.01
Armata announced receipt of $3.7 million in non-dilutive funding from the U.S. Department of War to support Phase 3 development of AP-SA02, bringing cumulative DoW funding to $32.4 million. This is a material operational and strategic milestone for a late-stage biotech company advancing a clinical-stage therapeutic candidate, but does not fit neatly into the specific financial categories (debt_issuance, dilutive_issuance, dividend_distribution) or other named event types. The funding is non-dilutive and represents government support for clinical development rather than a traditional financing event.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-09-23
Item 8.01
Ivanhoe Electric released an updated Preliminary Feasibility Study (PFS) for its Santa Cruz Copper Project in Arizona on September 23, 2026, prepared by qualified third-party engineering firms in accordance with SEC S-K 1300 mining disclosure regulations. The 2026 PFS replaces the prior technical report dated June 23, 2025 and includes updated mineral resource and reserve estimates, mining methods, processing flowsheets, and capital and operating cost estimates, representing a material advancement in the company's project development and strategic direction.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-09-23
Item 2.02
This is a clear earnings release disclosing Cracker Barrel's fourth quarter and full-year fiscal 2026 financial results, including revenue ($849.3M for Q4, $3.32B for full year), net income ($12.2M for Q4, $31.7M for full year), and earnings per share ($0.54 diluted for Q4, $1.40 for full year), along with fiscal 2027 outlook. The press release is furnished as Exhibit 99.1 and is the primary disclosure under Item 2.02.
View raw filing on EDGAR →
8-K
Cybersecurity Incident
confidence 98%
filed 2026-09-23
Item 1.05
The filing explicitly discloses a material cybersecurity incident under Item 1.05, involving social engineering attacks that led to unauthorized access and potential exfiltration of private patient, employee, provider, and business information. The Company determined the incident is material as of September 22, 2026, due to the sensitive nature of the accessed data and potential impacts on business operations, regulatory compliance, and reputation—all hallmarks of a material cybersecurity incident requiring 8-K disclosure.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-09-23
Item 8.01
CytoSorbents regained compliance with Nasdaq's minimum bid price requirement ($1.00 per share) as of September 22, 2026, after 10 consecutive trading sessions at or above that threshold. However, the company remains non-compliant with the Market Value of Listed Securities (MVLS) requirement of $35 million and has until December 28, 2026 to regain compliance or face delisting notification.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-09-23
EX-99.1
The exhibit announces the appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to the Board of Directors as strategic AI advisor. These are discrete executive and board appointments that would materially affect investor assessment of the company's leadership and strategic direction, particularly given the appointees' prominent backgrounds (Hart from Eli Lilly's genetic medicines team; Wolf as co-founder and CSO of Hugging Face) and their direct relevance to ProQR's stated AI strategy for its Axiomer RNA editing platform.
View raw filing on EDGAR →
8-K
Workforce Reduction
confidence 95%
filed 2026-09-23
Item 2.05
Adagio Medical announced a workforce reduction of 25 of 43 full-time employees (58% reduction) effective September 23, 2026, with estimated cash expenditures of approximately $1.3 million in severance, benefits, and related costs as part of a restructuring plan to extend capital resources.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-09-23
Item 8.01
The Company initiated a formal process to explore strategic alternatives, explicitly including acquisition, merger, business combination, or other transaction to maximize shareholder value. The concurrent workforce reduction and conversion price adjustment on Senior Secured Convertible Notes reflect preparation for a potential transaction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-23
Item 5.02
Alan M. Sebulsky was appointed to the Board of Directors as a Class I director effective September 23, 2026, bringing 40+ years of healthcare investment and biopharmaceutical portfolio management experience, including prior board service at Jazz Pharmaceuticals and Arrow International.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-09-23
Item 3.03
The Company's Board and stockholders approved a reverse stock split at a 1-for-150 ratio, with the Certificate of Amendment becoming effective on September 21, 2026. This materially modifies the rights and economic interests of security holders by consolidating shares and represents a significant capital structure change.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-09-23
Item 1.01
This Item 1.01 discloses the entry into multiple material definitive agreements in connection with the issuance of $991.83 million in asset-backed notes (Class A-1, A-2-A, A-2-B, A-3, and A-4) by Volkswagen Auto Lease Trust 2026-B on September 22, 2026. The core transaction involves the creation of a new direct financial obligation through the issuance of debt securities, supported by a comprehensive set of transaction documents including an indenture, servicing agreements, and trust agreements. This is a classic debt issuance event under Item 1.01.
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 75%
filed 2026-09-23
BBVA announces partial execution of a share capital reduction resolution by cancelling 70,339,213 treasury shares (par value 34.5 million euros), reducing share capital from 2.735 billion to 2.700 billion euros. While technically a capital reduction rather than a traditional dividend, this represents a return of capital to shareholders through share cancellation—a form of capital distribution. The transaction was authorized at the March 2026 shareholder meeting and executed through the third tranche of a share repurchase program, materially affecting the company's capital structure and shareholder equity.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-09-23
Item 1.01
This filing discloses the entry into multiple material definitive agreements in connection with the issuance and sale of asset-backed securities (Notes in Classes A-1, A-2-A, A-2-B, A-3, A-4, B, and C) on September 23, 2026. The core transaction involves the creation of a direct financial obligation through an Indenture between the Trust and the Indenture Trustee, pursuant to which the Notes were issued. This is a classic debt issuance structured as an asset-backed securitization, with the Receivables Purchase Agreement, Sale and Servicing Agreement, and other ancillary agreements supporting the debt creation. The transaction is material to investors as it represents a significant capital-raising event for the registrant.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-09-23
Item 2.01
Zymeworks Inc. completed its acquisition of Theravance Biopharma, Inc. on September 22, 2026, with Theravance becoming a wholly owned subsidiary. Shareholders received $17.00 per share in cash plus contingent value rights (CVRs) tied to future licensing proceeds, commercial milestones, and royalties from ampreloxetine. The merger resulted in a change of control, delisting from Nasdaq, and modification of shareholder rights, with the CVR Agreement establishing the contingent consideration mechanism.
View raw filing on EDGAR →
8-K
Exec departure
confidence 85%
filed 2026-09-23
Item 5.02
Six directors resigned from Theravance Biopharma's Board in connection with the completion of the merger with Zymeworks Inc., including CEO Rick E Winningham. The departing directors were Rick E Winningham, Laurie Smaldone Alsup, Susannah Gray, Dean J. Mitchell, Donal O'Connor, and Deepa R. Pakianathan.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-09-23
Item 8.01
StratCap Digital Infrastructure REIT concluded its strategic alternatives review process and decided not to pursue a sale at this time, though the Board will continue to evaluate alternatives including asset sales, liability management, and potential special distributions.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-09-23
Item 1.01
Willdan Group's wholly owned subsidiary Energy Solutions entered into a Membership Interest Purchase Agreement on September 22, 2026, to acquire 100% of Mantis Intermediate Holdings, LLC for a base purchase price of $285 million in cash. This is a material acquisition transaction disclosed under Item 1.01, with a scheduled closing of October 30, 2026, subject to customary closing conditions including HSR antitrust clearance and debt financing. The transaction size and strategic nature make it material to investors.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 75%
filed 2026-09-23
The 6-K discloses a redemption and cancellation of 66,668 Class A ordinary shares (100% of shares issued in the August 2025 private placement for $6 million in Dogecoin) that occurred on September 22, 2026. While this is technically a share cancellation rather than a new issuance, it represents the resolution of a dilutive private placement transaction (the original August 2025 DOGE-funded securities purchase) that was material to the registrant's capital structure. The disclosure documents the full unwinding of that dilutive event through investor redemption rights.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-09-23
Item 5.02
Dean C. Fullerton, Chief Operating Officer of Plug Power Inc., notified the Company on September 17, 2026 of his resignation effective October 23, 2026 to accept a position elsewhere. The disclosure centers on the departure of a named executive officer from a senior operational role, with no compensatory arrangements or appointment of a successor disclosed. The COO position is material to a reasonable investor's assessment of the company's leadership and operational continuity.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 95%
filed 2026-09-23
EX-99.1
This exhibit is a Fourteenth Supplemental Indenture dated September 23, 2026, establishing a new series of debt securities: "5.650% Brookfield Finance Inc. Notes due 2031" with an aggregate principal amount of $600,000,000. The document creates a direct financial obligation through the issuance of senior notes, which is a material debt issuance event. The indenture specifies the terms, conditions, covenants, and payment obligations for these notes, including interest rate, maturity date, and change-of-control provisions.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-09-23
Item 8.01
AMC announced the pricing of $2,000 million of 8.875% first lien notes due 2031 and $850 million of first lien term loans under a new facility, together with a previously announced $1,120 million second lien term loan facility. These are new direct financial obligations created by the company. The proceeds will be used to refinance existing debt, redeem notes, and repay term loans, representing a material debt restructuring transaction typical of debt_issuance disclosures.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-23
Item 8.01
Ionis announced positive prespecified interim results from the Phase 3 IMAgINATION study for sefaxersen in IgA nephropathy, demonstrating statistically significant proteinuria reduction versus placebo at 37 weeks. This material clinical milestone for the partnered investigational drug program (licensed to Roche) could support regulatory approval prospects and future sales milestone payments.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-09-23
EX-99.1
The exhibit discloses the results of an Extraordinary General Meeting held on 23 September 2026 at which shareholders passed a resolution to appoint Mr. Mikael Øpstun Skov as a Director of Hafnia Limited. This is a clear executive/board appointment event requiring disclosure under Item 5.02 equivalent governance rules.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-09-23
EX-99.1
This exhibit is a press release announcing Robin Energy Ltd.'s financial results for Q2 2026 and the first half of 2026. It discloses net income of $5.6 million for Q2 and $6.1 million for H1 2026, with detailed revenue, expense, and operational metrics. The document explicitly states "Robin Energy Ltd. Reports Net Income of $5.6 Million for the Three Months Ended June 30, 2026" and includes comprehensive financial tables and management commentary on earnings performance—the hallmark of an earnings release event.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 94%
filed 2026-09-23
EX-99.1
Hafnia Limited announced a contemplated offering of approximately USD 300 million in ordinary shares through an accelerated bookbuilding process, structured as a private placement under the Company's effective Form F-3 shelf registration statement. The offering will be supported by a share lending agreement with BW Group Limited to facilitate settlement, and proceeds will be used to strengthen the balance sheet and fund strategic opportunities.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 97%
filed 2026-09-23
Item 5.07
Bio-Techne shareholders voted on September 23, 2026 to approve the Merger Agreement with Merck KGaA, with 121,929,544 votes in favor and 1,208,817 against (78.55% quorum attendance). This shareholder approval of the material acquisition is highly material to investors.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-09-23
Item 1.01
This Item 1.01 discloses entry into an Amendment to a Material Definitive Agreement modifying the structure of a previously announced merger between Centerspace and Independence Realty Trust. The amendment implements an "Alternative Structure" for the Company Merger whereby Centerspace merges into IRT Merger Sub (rather than the reverse), fundamentally altering the transaction mechanics. This is a material M&A event affecting the registrant's ownership and control structure, requiring shareholder approval and Form S-4 registration.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 95%
filed 2026-09-23
EX-99.1
Highlander Silver has executed a mandate letter with Natixis CIB for a $330 million senior secured project finance facility to fund development of the Corani Silver Project, with an additional $100 million cost overrun facility. This represents creation of a new direct financial obligation—a structured debt facility—which is the hallmark of debt_issuance. The facility is subject to definitive documentation and closing expected in Q1 2027, making it a material financing event for a mining development company.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-23
EX-99.1
Optimi announced completion of a cGMP manufacturing batch of psilocybin capsules that will supply both a Health Canada-approved Phase 2 clinical trial for major depressive disorder and commercial supply to Australian licensed clinics. This is a material operational milestone demonstrating the company's ability to manufacture regulated psychedelic products at scale and simultaneously serve clinical and commercial channels, but it does not fit neatly into predefined event categories—it is neither a discrete clinical trial initiation (which would be operational_other anyway), a product approval, nor a financial event. The disclosure is material because it evidences the company's regulatory compliance, manufacturing capability, and revenue-generating commercial operations in Australia.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-23
EX-99.1
This press release discloses material operational and strategic updates across OR Royalties' portfolio of over 200 royalties and streams, including first gold production at Cuiú Cuiú (September 10, 2026), imminent production at Amulsar, positive construction decisions at Cariboo, and multiple permitting milestones (Hermosa, South Railroad, San Antonio, White Pine North). The exhibit also announces a strategic alliance with Solidcore Resources at the Japan Gold Portfolio with a $3 million royalty acquisition. These are discrete operational and development milestones affecting the registrant's asset base and future cash flows, but do not fit the specific event categories (earnings_release, M&A, exec changes, impairment, etc.). The disclosure is material to investors assessing the company's portfolio quality and production pipeline.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-23
Item 5.02
Five Below elected Scott Settersten, former CFO of Ulta Beauty with 15 years at PwC, to its Board of Directors and Audit Committee, effective September 21, 2026. The appointment includes an initial equity grant of 545 restricted stock units and represents a material governance event affecting board composition and financial oversight.
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 95%
filed 2026-09-23
EX-99.1
The exhibit discloses procedural details regarding a dividend distribution of $0.50 per ordinary share (approximately $10 million) previously announced on August 12, 2026, with payment expected on October 14, 2026. The announcement focuses on Israeli withholding tax procedures and reduced tax rates available to eligible shareholders under a ruling from the Israeli Tax Authority. This is a material dividend distribution event affecting shareholders' cash receipts and tax treatment.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-09-23
EX-99.1
IM Cannabis has entered a non-binding Letter of Intent to acquire 51% of Space Defense Innovations LLC, a Polish company operating in the unmanned aerial systems (UAS) sector. The transaction involves acquisition of control through equity securities and warrants, with a five-year call option for the remaining shares, representing a material acquisition activity that would affect investor assessment of the company's strategic direction and capital deployment.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-09-23
Innoviz received a Nasdaq notification on September 22, 2026, granting an additional 180-day compliance period (until March 22, 2027) to regain compliance with the minimum bid price requirement of $1.00 per share. The company failed to regain compliance during the initial 180-day period ending September 21, 2026, and now faces delisting risk if it cannot achieve the required bid price or effect a reverse split before the extended deadline. This is a material disclosure of continued listing failure and delisting risk under Item 3.01 equivalent.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-09-23
EX-99.1
The exhibit announces that IM Cannabis has regained compliance with Nasdaq's minimum bid price requirement (Rule 5550(a)(2)) after the closing bid price remained at $1.00 or greater for 18 consecutive business days. This disclosure directly addresses a delisting risk — the company had previously fallen below the $1.00 minimum and faced potential delisting, and this notice confirms restoration of compliance and closure of the deficiency matter. Material to investors as it resolves an existential listing threat.
View raw filing on EDGAR →
8-K
Exec departure
confidence 92%
filed 2026-09-23
Item 5.02
Owen James, President of PRA Group Europe, notified the Company of his intent to retire from his role effective December 31, 2026. This is a departure of a named officer from an executive position. While he will serve in an advisory capacity through March 31, 2027, the principal disclosed action is his retirement from the President role, making this an exec_departure event. The departure of a regional president is material to investors assessing management continuity and operational leadership.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-09-23
Item 8.01
Beyond Meat entered into exchange agreements to convert approximately $15.0 million principal of 0% Convertible Senior Notes due 2027 into common stock, with 1,097,444 shares issued initially and up to 848,265 additional shares potentially issued in final settlement, using the Section 4(a)(2) private placement exemption.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-09-23
Item 5.02
Sean Maduck, President of Corcept Endocrinology, resigned effective October 1, 2026, after 14 years with the company. The filing also discloses a consulting arrangement and continued vesting of stock options as ancillary arrangements tied to the resignation.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-09-23
Item 7.01
Justin Gunn was appointed as President of the Endocrinology division, effective October 1, 2026, with a reporting line to the CEO and membership on the Executive Team.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-23
Item 7.01
PowerCompute disclosed a fleet efficiency upgrade program involving installation of 1,000 new Bitmain miners in September 2026 and an order for 940 additional miners for October, expected to increase total hashrate by approximately 11.8% over June 30, 2026 baseline. The company estimates incremental revenue capacity of approximately $1.2 million per year from these new machines. This is a material operational and strategic business event involving capital deployment and capacity expansion, but does not fit the specific categories of earnings release, M&A activity, workforce reduction, or other named event types. The disclosure of Bitcoin holdings (323 BTC valued at $27.8 million) and funding from cash on hand and Bitcoin holdings supports the materiality of this operational initiative.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-09-23
Item 5.07
This Item 5.07 discloses the results of a special meeting of stockholders held on September 22, 2026, where shareholders voted on three proposals: (1) adoption of a merger agreement with Fertitta Gaming Holdco, LLC at $31.00 per share plus potential additional consideration; (2) advisory approval of merger-related executive compensation; and (3) adjournment authority. The Merger Proposal received 133.3 million votes in favor (65.4% of outstanding shares), representing clear shareholder approval of a material acquisition. This is a textbook shareholder vote results disclosure under Item 5.07.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-09-23
Item 5.07
This is a clear disclosure of shareholder vote results from Culp, Inc.'s annual meeting held on September 23, 2026. The filing reports voting outcomes for three proposals: (i) election of seven directors, (ii) ratification of Grant Thornton LLP as independent auditors for fiscal 2027, and (iii) an advisory Say-on-Pay vote on named executive officer compensation. The detailed voting tallies (shares voted for/withheld, broker non-votes, and for/against/abstain counts) are the core content of Item 5.07, which is the standard disclosure vehicle for shareholder meeting results.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 85%
filed 2026-09-23
Item 8.01
Mills Music Trust issued a Quarterly Distribution Report disclosing a distribution to Unit Holders of $573,382 ($2.0647 per Trust Unit) from royalty payments received from Sony Music Publishing. This is a routine periodic distribution of income to trust beneficiaries, consistent with the trust's ordinary operations as a royalty-income vehicle. While material to unitholders, it represents a standard dividend/distribution event rather than an extraordinary financial or operational occurrence.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 95%
filed 2026-09-23
Item 4.01
The filing discloses the dismissal of WithumSmith+Brown, PC as the independent registered public accounting firm effective immediately on September 21, 2026, and the concurrent engagement of Grassi & Co., Certified Public Accountants, P.C. as the new auditor. This is a classic auditor change under Item 4.01. While the prior auditor's reports contained an explanatory paragraph regarding substantial doubt about going concern, the filing explicitly states there were no disagreements or reportable events, indicating the change itself is not driven by audit disputes. The change is material because auditor identity and continuity affect investor confidence in financial reporting.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-23
Item 3.02
The filing discloses an unregistered sale of equity securities (common stock) pursuant to Item 3.02, with an aggregate offering price of $8.7 million. The shares are being issued under subscription agreements to existing investors via capital calls, exempt from Securities Act registration under Section 4(a)(2) and Regulation D. This is a classic dilutive issuance of unregistered equity to raise capital.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-09-23
Item 1.01
REGENXBIO settled material patent infringement litigation with Sarepta Therapeutics and Catalent regarding U.S. Patents 10,526,617 and 11,680,274 related to SRP-9001 (ELEVIDYS). The settlement involves a $39.0 million payment to the Company and termination with prejudice of all ongoing patent litigation, along with mutual covenants not to sue. This is a material litigation settlement that would affect a reasonable investor's assessment of the Company's patent portfolio and financial position.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-23
Item 7.01
Evommune announced a late-breaker oral presentation of Phase 2a clinical trial data for EVO301 in atopic dermatitis at the EADV Congress. This is a material clinical development milestone for a clinical-stage biotech company, as positive Phase 2a data and conference presentation represent significant progress in the drug development pipeline. The disclosure emphasizes "positive top-line data" and advancement toward Phase 2b studies, which would affect investor assessment of the company's pipeline value and commercial prospects. This is operational/strategic in nature rather than fitting a specific financial, governance, or legal category.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-09-23
Item 2.01
Zymeworks completed its acquisition of Theravance Biopharma on September 22, 2026, advancing its strategy to build a diversified revenue-generating biotechnology company. The transaction includes a Contingent Value Rights Agreement governing CVRs tied to ampreloxetine monetization and commercial milestones, and a $350 million senior secured Note Purchase Agreement with OCM IP Healthcare Portfolio LP.
View raw filing on EDGAR →
8-K
Material Litigation
confidence 92%
filed 2026-09-23
Item 1.01
The filing discloses settlement of material patent infringement litigations involving Sarepta's gene therapy product ELEVIDYS and UPenn Patents. The Company had already recorded a $39.0 million litigation contingency charge in Q2 2026, and the settlement agreement resolves pending patent infringement claims and inter partes review proceedings with a $39.0 million payment to REGENXBIO, plus a covenant not to sue regarding AAVrh74-based capsid products. This is a material litigation settlement that would affect investor assessment of the registrant's patent position and product commercialization risk.
View raw filing on EDGAR →